TSX runs higher on rate cut expectations
Smith & Nephew (LSE:SN, NYSE:SNN) announced Thursday the appointment of Dr Garheng Kong to its Board as an independent non-executive director and member of the Audit Committee, effective September 1, 2025. The information is based on a press release statement filed with the U.S. Securities and Exchange Commission.
Dr Kong is currently managing partner and co-founder of HealthQuest Capital. He also serves as lead independent director at Laboratory Corporation of America (LabCorp) and as a non-executive director at Xeris Biopharma Holdings Inc, Lunit Inc, and IKS Health. His previous roles include managing general partner at Sofinnova Investments, Inc, non-executive director at Venus Concept, Inc, Alimera Sciences, and Avedro, Inc, and chair of Histogenics Corporation.
Rupert Soames, Chair of Smith & Nephew, said in the statement, "We are delighted to welcome Garheng to our Board. He has wide experience in the medtech and biopharma sectors and has significant clinical, technical and investment expertise having served as an executive, non-executive and as an investor, supporting innovation and growth across a number of successful businesses."
The company noted that no disclosure obligations arise under the UK Listing Authority’s Listing Rules in respect of the new appointment.
Smith & Nephew is a medical technology company operating in about 100 countries, with reported annual sales of $5.8 billion in 2024. The company is listed on the London Stock Exchange and the New York Stock Exchange.
This article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.